Skip to main content
v2026.11,986 entries · CC-BY 4.0

FDA Inactive Ingredient Database (IID): What It Lists and How to Read It

What the FDA Inactive Ingredient Database lists, how to read potency versus daily exposure, and what an excipient listing does and does not mean.

Written and maintained by CASRAI Editorial Board

Published

On this page

The FDA Inactive Ingredient Database (IID) is the FDA’s list of inactive ingredients (excipients) that are present in FDA-approved drug products, shown by route of administration and dosage form with a maximum potency or maximum daily exposure value. Formulators and regulatory staff use it to see whether an excipient has already appeared in an approved product for a given route, and at what level. The FDA publishes it as a searchable web tool and as downloadable quarterly files.

What the FDA Inactive Ingredient Database is and who runs it

The IID is maintained by the FDA’s Center for Drug Evaluation and Research. According to the FDA’s database FAQ (content dated 2022-01-26), it “provides information on inactive ingredients present in FDA-approved drug products.” The FAQ defines an inactive ingredient as any component of a drug product other than the active ingredient, which matches the wording of the federal drug regulations: 21 CFR 210.3(b)(8) says an inactive ingredient “means any component other than an active ingredient”, while 210.3(b)(7) defines an active ingredient as a component intended to furnish pharmacological activity or other direct effect in diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body.

The database’s stated purpose, in the FDA’s question-and-answer document on its 2019 enhancements, is to show excipient levels that may be referenced during drug development. Routes of administration and dosage forms in the IID are derived from current approved labeling, and the FDA has standardized those terms to the vocabulary used in structured product labeling (SPL). Related background: structured product labeling (SPL) and DailyMed, where approved labeling is published.

Who can use it (eligibility)

There is no application or eligibility test. The IID is published as ordinary public pages on the FDA website: an online search tool at accessdata.fda.gov and a download page on fda.gov. It is aimed at people developing or reviewing drug formulations, so the practical audience is formulation scientists, regulatory affairs staff, contract developers and academic researchers working on drug products, but nothing on the FDA pages restricts who may look excipients up.

What the database lists

Each record is one inactive ingredient in one route and dosage form combination. The data table below sets out the seven fields in the download file and what each one contains. Three points about content matter more than the field list:

  • Final dosage forms only. The FDA states that the IID covers inactive ingredients in final dosage forms; it does not cover contaminants.
  • Not a formula. The IID algorithm retrieves the largest value for each excipient and route and, per the FDA, does not reveal any individual product’s formulation.
  • Not every ingredient has a UNII or a plain name. Some ingredients lack a Unique Ingredient Identifier. Proprietary excipient systems (the FAQ gives Opadry as an example) are treated as products and show “N/A” where a UNII would be.

Some substances, alcohol being the FDA’s example, can be an active ingredient in one product and an inactive ingredient in another, so the same name can appear in the IID without implying anything about its role elsewhere.

What a listing means and what it does not

An excipient that appears in the IID for a route is, in the FDA’s words, “not considered new” for that route once it has been used in an approved product, and a product that uses it at or below the listed level may receive a less extensive review of that ingredient. The FAQ is equally explicit about the limit: a listing is not a safety determination, because the presence of an ingredient in an approved product reflects the sponsor’s judgment and the FDA’s review of that product, not a standalone clearance of the excipient for any use.

Three practical consequences follow from the FDA’s statements:

  • An ingredient absent from the IID for your route may still be usable, but it is likely to be treated as a new excipient for that route, which is a development decision to discuss with the FDA, not something the database answers.
  • A listed ingredient at a higher level than the listed maximum is outside what the database shows has been approved.
  • The listing does not tell you which products contain the ingredient. Product lookups belong in other FDA resources such as DailyMed, the Orange Book or the FDA NDC Directory (see the table below).

Maximum potency, maximum daily exposure and MDI

The potency column is the field people misread most often. The FDA’s FAQ and its 2019 enhancement Q and A describe three related quantities:

Quantity What the FDA says it is Watch for
Maximum potency The highest unit-dose amount of the excipient in the approved products behind the listing; for topical products, the highest percentage in the formula. A dynamic value that can change from one publication to the next. It is not the daily amount unless the product is dosed as a single unit.
Maximum daily exposure (MDE) The total amount of the excipient taken or used in a day: the amount per dosage unit multiplied by the maximum number of units per day. Where an MDE is available it is displayed instead of maximum potency. The FDA says the two values are not linked, and an MDE can also change between publications.
Maximum daily intake (MDI) The term sometimes used for the MDE of an oral product. Same quantity, different name; do not treat it as a third number.

The practical rule is to read the potency column together with the route and dosage form on the same row, and to remember that a figure labelled potency may be a per-unit maximum while a figure that is an MDE is already a per-day maximum. The two columns are not interchangeable.

How to look up an excipient (search and download steps)

  1. Choose the tool. The online search suits a single excipient. The download suits batch comparison against a formulation list.
  2. Search. The search accepts any portion of an ingredient name, with a minimum of three characters. Results are sorted by ingredient, then route, then dosage form.
  3. Download. The download page offers comma-delimited text and Excel files, each under 2 MB when unzipped, with the seven fields described in the table below.
  4. Match route and dosage form first. Because the same ingredient can be listed for several routes and forms, filter to your product’s route and dosage form before reading the potency or MDE value.
  5. Record the file or update you used. Values can be revised between updates, so a development file should note which quarterly release was consulted.
  6. Report errors. The FDA search page directs corrections to [email protected] (type the address into your own mail client).

Update cycle and versions

The FAQ states that the database is updated quarterly, by the tenth working day of April, July, October and January. Earlier quarterly files stay on the download page. As described on the FDA download page on 2026-11-17, the current file is the October 2026 update, quarterly files are listed back to April 2016, and files for 2009 through 2015 are in the FDA archive.

The FDA’s 2019 Q and A also records a change in scope: standardizing the vocabulary reduced the number of route and dosage-form entries from more than 14,000 to about 10,000. The FDA says values decrease only to correct an error, and it announced that MDE would be added to the database, displayed in place of maximum potency where available.

Common mistakes

  • Treating a listing as an approval or a safety clearance. The FDA says it is neither.
  • Reading maximum potency as the daily amount. It is a unit-dose or percentage figure; the MDE is the daily figure, and the two are not linked.
  • Ignoring route. An excipient listed for oral use does not establish anything about injectable or ophthalmic use.
  • Treating an old download as current. Values are updated quarterly and can change.
  • Expecting product names or formulas. The IID reveals neither.
  • Searching by short or partial strings and stopping at the first row. Results span many routes and dosage forms.
Question you have Where to look
Which excipients, at what levels, are in approved products by route? FDA Inactive Ingredient Database (this page).
What does the current approved labeling for a product say? DailyMed.
Which approved drug products exist, and how are they listed? Orange Book.
What is the National Drug Code for a product? FDA NDC Directory.
How are dosage forms and formulation choices described? Drug formulation.

Sources

Data: Fields in the FDA Inactive Ingredient Database download file

The seven fields of the FDA IID quarterly download file, what each holds and the FDA's stated caveat for it, compiled from the FDA download page, the IID FAQ and the 2019 enhancements Q&A.

Coverage: United States.

Fields in the FDA Inactive Ingredient Database download file
FieldWhat it holdsFDA caveat or note
Inactive ingredientName of the excipientSearch matches any portion of a name, minimum three characters
RouteRoute of administration, standardized to SPL termsDerived from current approved labeling
Dosage formDosage form of the approved product, standardized to SPL termsFinal dosage forms only; no contaminants
CAS numberChemical Abstracts Service registry numberNot stated as present for every ingredient
UNIIFDA Unique Ingredient IdentifierNot all ingredients have one; proprietary systems such as Opadry show N/A
Potency amountMaximum potency, or maximum daily exposure where availableThe two values are not linked; values can change between updates
Potency unitUnit of the potency amountTopical products use the highest percentage in the formula

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about FDA Inactive Ingredient Database (IID): What It Lists and How to Read It

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →